Related Experiment Video

Updated: Jun 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments

Stephan H Schirmer1, Magnus Baumhäkel, Hans-Ruprecht Neuberger

  • 1Klinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. Stephan.Schirmer@uks.eu

Journal of the American College of Cardiology
|December 15, 2010
PubMed

Insights

New oral anticoagulants show promise for preventing stroke in atrial fibrillation (AF) patients. These drugs may offer a safer and more effective alternative to traditional vitamin K antagonists (VKAs).

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is a common heart rhythm disorder and a significant risk factor for ischemic stroke.
  • Current stroke prevention in AF relies on antithrombotic therapy, primarily aspirin or vitamin K antagonists (VKAs).
  • VKAs have limitations including a narrow therapeutic range and the need for regular monitoring, impacting their effectiveness and safety.

Purpose of the Study:

  • To review recent advancements in directly acting oral anticoagulant (DOAC) drugs.
  • To evaluate the potential of DOACs to replace VKAs for stroke prevention in patients with AF.

Main Methods:

  • Review of current literature and phase III clinical trial data for DOACs.
  • Focus on direct thrombin antagonists (e.g., dabigatran) and factor Xa inhibitors (e.g., rivaroxaban, apixaban, betrixaban, edoxaban).

Main Results:

  • Phase III trial data for dabigatran demonstrate non-inferior efficacy compared to VKAs for preventing stroke and systemic embolism in AF patients.
  • DOACs represent a new class of anticoagulants with potential advantages over VKAs.

Conclusions:

  • Directly acting oral anticoagulants are emerging as viable alternatives to VKAs for stroke prevention in AF.
  • Further research and clinical data will solidify the role of DOACs in managing AF patients at risk of stroke.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...